Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
SAGE Therapeutics (SAGE) has issued an update.
Sage Therapeutics, Inc. recently made a strategic move by amending its 2016 Inducement Equity Plan, reducing the number of shares allocated for issuance and setting a cut-off date for future awards. With the reduction to 428,074 shares, the company also declared that no new awards will be issued after April 16, 2024. This decision reflects a pivotal change in the company’s stock allocation strategy.
See more insights into SAGE stock on TipRanks’ Stock Analysis page.